{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:49:19Z","timestamp":1787021359771,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1245\/s10434-025-18714-7","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T14:42:00Z","timestamp":1763476920000},"page":"2653-2662","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8476-3985","authenticated-orcid":false,"given":"Hironobu","family":"Suto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kobara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihito","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Kumamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"1","key":"18714_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"18714_CR2","doi-asserted-by":"crossref","unstructured":"Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2:16022.","DOI":"10.1038\/nrdp.2016.22"},{"key":"18714_CR3","doi-asserted-by":"crossref","unstructured":"Unno M, Motoi F, Matsuyama Y, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer: results of the randomized phase II\/III prep-02\/JSAP05 trial. Ann Surg. 2025.","DOI":"10.1097\/SLA.0000000000006730"},{"issue":"16","key":"18714_CR4","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763\u201373.","journal-title":"J Clin Oncol"},{"issue":"17","key":"18714_CR5","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1002\/cncr.30117","volume":"122","author":"JM Cloyd","year":"2016","unstructured":"Cloyd JM, Crane CH, Koay EJ, et al. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016;122(17):2671\u20139.","journal-title":"Cancer"},{"issue":"9","key":"18714_CR6","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1245\/s10434-017-5921-4","volume":"24","author":"K Okano","year":"2017","unstructured":"Okano K, Suto H, Oshima M, et al. A Prospective phase II trial of neoadjuvant S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2017;24(9):2777\u201384.","journal-title":"Ann Surg Oncol"},{"key":"18714_CR7","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 1.2024. Published December 18, 2023. Accessed June 11, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf"},{"issue":"3","key":"18714_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/MPA.0000000000002011","volume":"51","author":"H Suto","year":"2022","unstructured":"Suto H, Okano K, Oshima M, et al. Efficacy and safety of neoadjuvant chemoradiation therapy administered for 5 versus 2 weeks for resectable and borderline resectable pancreatic cancer. Pancreas. 2022;51(3):269\u201377.","journal-title":"Pancreas"},{"issue":"5","key":"18714_CR9","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1097\/SLA.0000000000004535","volume":"276","author":"S Takahashi","year":"2022","unstructured":"Takahashi S, Ohno I, Ikeda M, et al. Neoadjuvant S-1 With concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: a phase II open-label multicenter prospective trial (JASPAC05). Ann Surg. 2022;276(5):e510\u20137.","journal-title":"Ann Surg"},{"key":"18714_CR10","unstructured":"Burgart LJ, Chopp WV, Jain D. Protocol for the examination of specimens from patients with carcinoma of the pancreas; 2021. Available at: www.cap.org\/protocols-and-guidelines\/cancer-reporting-tools\/cancer-protocol-templates. Accessed November 15, 2025."},{"issue":"11","key":"18714_CR11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/archsurg.1992.01420110083017","volume":"127","author":"DB Evans","year":"1992","unstructured":"Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127(11):1335\u20139.","journal-title":"Arch Surg"},{"issue":"10041","key":"18714_CR12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248\u201357.","journal-title":"Lancet"},{"issue":"18","key":"18714_CR13","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"issue":"19","key":"18714_CR14","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"issue":"2","key":"18714_CR15","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187\u201396.","journal-title":"Ann Surg"},{"issue":"3","key":"18714_CR16","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.surg.2016.11.014","volume":"161","author":"C Bassi","year":"2017","unstructured":"Bassi C, Marchegiani G, Dervenis C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery. 2017;161(3):584\u201391.","journal-title":"Surgery"},{"issue":"9","key":"18714_CR17","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","volume":"8","author":"MHG Katz","year":"2022","unstructured":"Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. JAMA Oncol. 2022;8(9):1263\u201370.","journal-title":"JAMA Oncol"},{"key":"18714_CR18","doi-asserted-by":"crossref","unstructured":"Murakami T, Matsuyama R, Oshi M, et al. Comparison between neoadjuvant chemoradiotherapy and chemotherapy for patients with resectable pancreatic cancer. Ann Surg Oncol. 2025.","DOI":"10.1245\/s10434-025-17988-1"},{"issue":"13","key":"18714_CR19","doi-asserted-by":"publisher","first-page":"4498","DOI":"10.1245\/s10434-019-07735-8","volume":"26","author":"H Eguchi","year":"2019","unstructured":"Eguchi H, Takeda Y, Takahashi H, et al. A prospective, open-label, multicenter phase 2 trial of neoadjuvant therapy using full-dose gemcitabine and S-1 concurrent with radiation for resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2019;26(13):4498\u2013505.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"18714_CR20","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jacbts.2018.01.014","volume":"3","author":"BP Venkatesulu","year":"2018","unstructured":"Venkatesulu BP, Mahadevan LS, Aliru ML, et al. Radiation-induced endothelial vascular injury: a review of possible mechanisms. JACC Basic Transl Sci. 2018;3(4):563\u201372.","journal-title":"JACC Basic Transl Sci"},{"issue":"5","key":"18714_CR21","first-page":"437","volume":"71","author":"K Wang","year":"2021","unstructured":"Wang K, Tepper JE. Radiation therapy-associated toxicity: etiology, management, and prevention. CA Cancer J Clin. 2021;71(5):437\u201354.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"18714_CR22","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1002\/cncr.26651","volume":"118","author":"D Chatterjee","year":"2012","unstructured":"Chatterjee D, Katz MH, Rashid A, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012;118(12):3182\u201390.","journal-title":"Cancer"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18714-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18714-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18714-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:39:50Z","timestamp":1770899990000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18714-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["18714"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18714-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hiroyuki Okuyama received lecture fees from Novartis Pharma, TAIHO Pharma, AstraZeneca, Chugai Pharmaceutical Co., Ltd., Incyte Biosciences Japan, Gardant Health Japan, MIYARISAN Pharmaceutical Co, Otsuka Pharmaceutical Factory, Inc, Merck & Co., Inc, and NIHON Servier. Akihito Tsuji has relevant financial activities outside the submitted work with Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan Co., Ltd., Merck Biopharma Co., Ltd., Sanofi Corporation, and Bristol-Myers Squibb.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}